BACKGROUND: Mutations of voltage-gated sodium channel alpha(II) gene, SCN2A, have been described in a wide spectrum of epilepsies. While inherited SCN2A mutations have been identified in multiple mild epilepsy cases, a de novo SCN2A-R102X mutation, which we previously reported in a patient with sporadic intractable childhood localization-related epilepsy, remains unique. To validate the involvement of de novo SCN2A mutations in the etiology of intractable epilepsies, we sought to identify additional instances. METHODS: We performed mutational analyses on SCN2A in 116 patients with severe myoclonic epilepsy in infancy, infantile spasms, and other types of intractable childhood partial and generalized epilepsies and did whole-cell patch-clamp recordings on Na(v)1.2 channels containing identified mutations. RESULTS: We discovered 2 additional de novo SCN2A mutations. One mutation, SCN2A-E1211K, was identified in a patient with sporadic infantile spasms. SCN2A-E1211K produced channels with altered electrophysiologic properties compatible with both augmented (an approximately 18-mV hyperpolarizing shift in the voltage dependence of activation) and reduced (an approximately 22-mV hyperpolarizing shift in the voltage dependence of steady-state inactivation and a slowed recovery from inactivation) channel activities. The other de novo mutation, SCN2A-I1473M, was identified in a patient with sporadic neonatal epileptic encephalopathy. SCN2A-I1473M caused an approximately 14-mV hyperpolarizing shift in the voltage dependence of activation. CONCLUSIONS: The identified de novo mutations SCN2A-E1211K, -I1473M, and -R102X indicate that SCN2A is an etiologic candidate underlying a variety of intractable childhood epilepsies. The phenotypic variations among patients might be due to the different electrophysiologic properties of mutant channels.
BACKGROUND: Mutations of voltage-gated sodium channel alpha(II) gene, SCN2A, have been described in a wide spectrum of epilepsies. While inherited SCN2A mutations have been identified in multiple mild epilepsy cases, a de novo SCN2A-R102X mutation, which we previously reported in a patient with sporadic intractable childhood localization-related epilepsy, remains unique. To validate the involvement of de novo SCN2A mutations in the etiology of intractable epilepsies, we sought to identify additional instances. METHODS: We performed mutational analyses on SCN2A in 116 patients with severe myoclonic epilepsy in infancy, infantile spasms, and other types of intractable childhood partial and generalized epilepsies and did whole-cell patch-clamp recordings on Na(v)1.2 channels containing identified mutations. RESULTS: We discovered 2 additional de novo SCN2A mutations. One mutation, SCN2A-E1211K, was identified in a patient with sporadic infantile spasms. SCN2A-E1211K produced channels with altered electrophysiologic properties compatible with both augmented (an approximately 18-mV hyperpolarizing shift in the voltage dependence of activation) and reduced (an approximately 22-mV hyperpolarizing shift in the voltage dependence of steady-state inactivation and a slowed recovery from inactivation) channel activities. The other de novo mutation, SCN2A-I1473M, was identified in a patient with sporadic neonatal epilepticencephalopathy. SCN2A-I1473M caused an approximately 14-mV hyperpolarizing shift in the voltage dependence of activation. CONCLUSIONS: The identified de novo mutations SCN2A-E1211K, -I1473M, and -R102X indicate that SCN2A is an etiologic candidate underlying a variety of intractable childhood epilepsies. The phenotypic variations among patients might be due to the different electrophysiologic properties of mutant channels.
Authors: A Escayg; B T MacDonald; M H Meisler; S Baulac; G Huberfeld; I An-Gourfinkel; A Brice; E LeGuern; B Moulard; D Chaigne; C Buresi; A Malafosse Journal: Nat Genet Date: 2000-04 Impact factor: 38.330
Authors: R Planells-Cases; M Caprini; J Zhang; E M Rockenstein; R R Rivera; C Murre; E Masliah; M Montal Journal: Biophys J Date: 2000-06 Impact factor: 4.033
Authors: Eric Herlenius; Sarah E Heron; Bronwyn E Grinton; Deborah Keay; Ingrid E Scheffer; John C Mulley; Samuel F Berkovic Journal: Epilepsia Date: 2007-03-26 Impact factor: 5.864
Authors: Ruwei Xu; Evan A Thomas; Misty Jenkins; Elena V Gazina; Cindy Chiu; Sarah E Heron; John C Mulley; Ingrid E Scheffer; Samuel F Berkovic; Steven Petrou Journal: Mol Cell Neurosci Date: 2007-03-13 Impact factor: 4.314
Authors: Louise A Harkin; Jacinta M McMahon; Xenia Iona; Leanne Dibbens; James T Pelekanos; Sameer M Zuberi; Lynette G Sadleir; Eva Andermann; Deepak Gill; Kevin Farrell; Mary Connolly; Thorsten Stanley; Michael Harbord; Frederick Andermann; Jing Wang; Sat Dev Batish; Jeffrey G Jones; William K Seltzer; Alison Gardner; Grant Sutherland; Samuel F Berkovic; John C Mulley; Ingrid E Scheffer Journal: Brain Date: 2007-03 Impact factor: 13.501
Authors: Pasquale Parisi; Alberto Verrotti; Maria Chiara Paolino; Rosa Castaldo; Filomena Ianniello; Alessandro Ferretti; Francesco Chiarelli; Maria Pia Villa Journal: Ital J Pediatr Date: 2011-12-19 Impact factor: 2.638
Authors: Julia Krushkal; Laura E Murphy; Frederick B Palmer; J Carolyn Graff; Thomas R Sutter; Khyobeni Mozhui; Collin A Hovinga; Fridtjof Thomas; Vicki Park; Frances A Tylavsky; Ronald M Adkins Journal: Behav Genet Date: 2014-01-23 Impact factor: 2.805
Authors: Katherine B Howell; Jacinta M McMahon; Gemma L Carvill; Dimira Tambunan; Mark T Mackay; Victoria Rodriguez-Casero; Richard Webster; Damian Clark; Jeremy L Freeman; Sophie Calvert; Heather E Olson; Simone Mandelstam; Annapurna Poduri; Heather C Mefford; A Simon Harvey; Ingrid E Scheffer Journal: Neurology Date: 2015-08-19 Impact factor: 9.910